干预措施有利于影响冠状动脉样硬化的演变. 对于通道阻塞剂的情况
1Department of Medicine, Montreal Heart Institute, Quebec, Canada.
Circulation
|December 1, 1992
概括
通道阻塞剂在治疗冠状动脉样硬化方面具有潜力. 临床试验表明,这些药物可能会减缓微小病变的进展,并减少新的冠状动脉病变的形成.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 通道阻塞剂 (CCB) 可能通过各种机制抑制动脉样硬化发展.
- 潜在的机制包括刺激胆固醇酸酶,改善内皮功能或抑制光滑肌肉细胞增殖.
研究的目的:
- 评估CCBs对人类冠状动脉样硬化进展的影响.
- 评估尼卡迪平和尼费迪平对冠状动脉病变演变的影响.
主要方法:
- 进行了两项临床试验:蒙特利尔心脏研究所试验和抗动脉样硬化疗法国际尼菲迪平试验.
- 这些试验评估了患者冠状动脉样硬化的进展和回归.
主要成果:
- 尼卡迪平没有影响整体动脉样硬化进展,但在最小的病变 (<或=20%的狭窄) 中减少了进展.
- 尼菲迪平对整体进展或回归没有影响,但降低了新冠状动脉病变的形成.
结论:
- 冠状动脉样管是治疗冠状动脉样硬化的一种有希望的治疗策略.
- 特定的CCB可能会影响动脉样硬化病变发展的不同方面.
相关概念视频
Antihypertensive Drugs: Action of Calcium Channel Blockers
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...


